O. Burgy (Dijon, France), M. Platé (London, United Kingdom), L. Organ (Nottingham (Nottinghamshire), United Kingdom), S. Rolandsson Enes (Burlington, United States of America)
Neutrophil extracellular traps contribute to pulmonary fibrosis induced by bleomycin
M. Suzuki (Chiba, Japan), J. Ikari (Chiba, Japan), R. Anazawa (Chiba, Japan), N. Tanaka (Chiba, Japan), Y. Katsumata (Chiba, Japan), A. Shimada (Chiba, Japan), E. Suzuki (Chiba, Japan), K. Tatsumi (Chiba, Japan)
|  |
SP-C deficiency causes early alveolar de-recruitment resulting in a combination of air spaces over-distension and spontaneous fibrotic remodeling in aging lungs
K. Sehlmeyer (Hannover, Germany), J. Ruwisch (Hannover, Germany), M. Ochs (Berlin, Germany), L. Knudsen (Hannover, Germany), E. Lopez Rodriguez (Hannover, Germany)
| |
Electroporation-mediated HGF gene transfer increases mesenchymal stem cell and decreases MMP24 levels in a bleomycin-induced lung injury model.
A. Gazdhar (Bern, Switzerland), K. Fytianos (Bern, Switzerland), S. Pantasis (Zurich, Switzerland), S. Mykoniati (Delemont, Switzerland), M. Bordoli (Zurich, Switzerland), F. Batty (St Gallen, Switzerland), K. Hostettler (Basel, Switzerland), T. Geiser (Bern, Switzerland)
| |
Biological- and imaging biomarkers of edema and fibrosis in a rat model of drug-induced interstitial lung disease (DIILD)
I. Mahmutovic Persson (Lund, Sweden), H. Falk Håkansson (Lund, Sweden), A. Örbom (Lund, Sweden), P. Önnervik (Lund, Sweden), J. Persson (Lund, Sweden), K. Von Wachenfeldt (Lund, Sweden), L. E. Olsson (Lund, Sweden)
| |
Use of Telemetry and Plethysmography to Assess Respiratory Function in Conscious Rats with Bleomycin-Induced Lung Fibrosis
M. Mcelroy (Edinburgh, United Kingdom), C. Lam (London, United Kingdom), I. Cranston (Edinburgh, United Kingdom), J. Baily (Edinburgh, United Kingdom), P. Aston (Guildford, United Kingdom), M. Nandi (london, United Kingdom), A. Milne (Edinburgh, United Kingdom)
| |
Quantitation of hydroxyproline in a mouse model of bleomycin-induced lung fibrosis: comparison with histological analysis
V. Bigatto (Verona, Italy), E. Manni (Verona, Italy), D. Pompilio (Verona, Italy), M. Brana' (Verona, Italy), A. Chalidou (Verona, Italy), J. Velden (Hamburg, Germany), M. Corsi (Verona, Italy), V. Russell (Verona, Italy), F. Andreetta (Verona, Italy)
| |
Automated histological image analysis for the assessment of bleomycin-induced pulmonary fibrosis in rodents
S. Pontis (Parma , Italy), F. Bignami (Parma , Italy), D. Miglietta (Parma , Italy), V. Pitozzi (Parma , Italy), P. Caruso (Parma , Italy), M. Pittelli (Parma , Italy), M. Bonatti (Parma , Italy), G. Villetti (Parma , Italy), M. Civelli (Parma , Italy), M. Trevisani (Parma , Italy)
| |
An orally available, highly selective 5-hydroxytryptamine 2B (5-HT2B) receptor antagonist ameliorating pulmonary and dermal fibrosis
C. Wenglén (Lund, Sweden), H. Arozenius (Lund, Sweden), L. Pettersson (Lund, Sweden), G. Ekstrom (Lund, Sweden)
|  |
Understanding of Pharmacokinetics and Exposure Drives use of Nintedanib as a Positive Control Reference Item in a Rat Model of Bleomycin-Induced Fibrosis
M. Mcelroy (Edinburgh, United Kingdom), J. Baily (Edinburgh, United Kingdom), O. Peris Serrano (Edinburgh, United Kingdom), A. Marsden (Edinburgh, United Kingdom), M. Briggs (Harlow, United Kingdom), I. Love (Edinburgh, United Kingdom), S. Madden (Edinburgh, United Kingdom), S. Gandi (Edinburgh, United Kingdom), M. Whitmarsh (Harlow, United Kingdom), A. Young (Harlow, United Kingdom)
| |
Fibroblast activation triggered by LPA results in matrix synthesis/fibrogenesis different from that of TGF-ß1
N. Gudmann (Herlev, Denmark), Y. Luo (Princeton, United States of America), J. Sand (Herlev, Denmark), G. Trujillo (Princeton, United States of America), B. Murphy (Princeton, United States of America), P. Cheng (Princeton, United States of America), M. Karsdal (Herlev, Denmark), M. Nielsen (Herlev, Denmark), D. Leeming (Herlev, Denmark), G. Jarai (Princeton, United States of America)
| |
Hypoxia-inducible factor pathway activation promotes bone-type collagen cross-linking in Idiopathic Pulmonary Fibrosis
C. Brereton (Southampton, United Kingdom), L. Yao (Southampton, United Kingdom), J. Bell (Southampton, United Kingdom), F. Conforti (Southampton, United Kingdom), A. Alzetani (Southampton, United Kingdom), A. Fabre (Dublin , Ireland), B. Marshall (Southampton, United Kingdom), L. Richeldi (Rome, Italy), D. Davies (Southampton, United Kingdom), Y. Wang (Southampton, United Kingdom), M. Jones (Southampton, United Kingdom)
| |
Erythropoietin (EPO) attenuates the immunohistochemical expression of autophagy antibodies in bleomycin (BLM), induced pulmonary fibrosis (PF) in rats
D. Tsavlis (Thessaloniki, Greece), D. Anestakis (Thessaloniki, Greece), P. Konstantinidou (Thessaloniki, Greece), K. Symeonidou (Thessaloniki, Greece), D. Koutsonikolas (Thessaloniki, Greece), A. Tzoumaka (Thessaloniki, Greece), E. Spandou (Thessaloniki, Greece)
| |
PAR-2 mediated interactions between mast cells and fibroblasts cause a switch in fibroblast morphology and cytokine profile
M. Bagher (Lund, Sweden), O. Rosmark (Lund, Sweden), L. Elowsson Rendin (Lund, Sweden), A. Nybom (Lund, Sweden), S. Wasserström (Lund, Sweden), C. Müller (Lund, Sweden), O. Hallgren (Lund, Sweden), L. Bjermer (Lund, Sweden), A. Larsson-Callerfelt (Lund, Sweden), G. Westergren-Thorsson (Lund, Sweden)
| |
Deletion of Activated Leukocyte Cell Adhesion Molecule (ALCAM/CD166) Aggravates Pulmonary Fibrosis
M. Kim (Seoul, Republic of Korea), J. Hong (Seoul, Republic of Korea), E. Kwak (Seoul, Republic of Korea), E. Kim (Seoul, Republic of Korea), K. Kim (Seoul, Republic of Korea), M. Sohn (Seoul, Republic of Korea)
| |
Elevated serum S100A4 levels in patients with silicosis
G. lingli (Tangshan, China), H. Liu (Tangshan, China), X. Hao (Tangshan, China)
| |
Investigating the role of AKAP13 on epithelial cell TGFß activation
L. Organ (Nottingham , United Kingdom), J. Porte (Nottingham , United Kingdom), A. John (Nottingham , United Kingdom), G. Jenkins (Nottingham , United Kingdom)
| |
The epigenetic modulator 5-aza-2’-deoxycytidine reduces the fibrotic response of human lung fibroblasts to TGFß1 in a novel, long term, 3D cell culture system.
M. Ward (Dublin, Ireland), D. Smart (Southampton, United Kingdom), J. Roberts (Southampton, United Kingdom), P. Monk (Southampton, United Kingdom), D. Davies (Southampton, United Kingdom), M. Jones (Southampton, United Kingdom), K. O'Reilly (Dublin, Ireland), J. Baugh (Dublin, Ireland)
| |
Targeting the Hippo signaling pathway to enhance ex vivo lung epithelial tissue regeneration and maturation
D. Gorman (Boston, MA, United States of America), T. Wu (Boston, MA, United States of America), H. Ott (Boston, MA, United States of America), S. Gilpin (Boston, MA, United States of America)
| |
Role of IL23 in the development of fibrotic interstitial lung disease
J. Lau (Rochester, United States of America), S. Wang (Rochester, United States of America), J. Davis (Rochester, United States of America), E. Matteson (Rochester, United States of America), R. Vassallo (Rochester, United States of America)
| |